MGTX
MeiraGTxDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bull case assumes positive clinical readouts and at least one partnering/licensing deal within three months that materially de-risks programs and accelerates milestones, prompting re-rating versus peers.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +4.6.
What can break
Clinical trial failure or safety signal
Momentum
75
Value
41
Sentiment
22
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.33 · Bull $9.38 · Bear $3.52
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-10-10 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $26.75
Why
Momentum75 · Δ7d +4.6
Value41 · Δ7d +0.1
Sentiment22 · Δ7d -1.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
75
34% active weight
Current posture
7d trendSoftening
Δ7d
+4.6
Δ21d
-7.3
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
22
33% active weight
Current posture
7d trendSoftening
Δ7d
-1.8
Δ21d
+6.7
Why this grade
Composite grade D. Momentum 74.9 / Value 41.1 / Sentiment 21.8
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$855.71M
Beta
1.38
Shares Out
80.49M
P/E (TTM) · Derived
-5.0
P/S (TTM)
22.17
P/FCF (TTM) · Derived
-7.02
Rev YoY
-96.2%
EPS YoY
-13.7%
Gross Margin
+41.0%
Op Margin
-597.9%
Net Debt
-$30.44M
Current Ratio
0.22
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology